News

Our CEO, Dr. Pi-Hui Liang, Won the Outstanding Research Award

TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, proudly announced that our funder and CEO, Dr. Pi-Hui Liang, awarded “Outstanding Research Award”.

Dr. Pi-Hui Liang leads her team, leaning on their erudite knowledge in medical chemistry, drug formulation, and regulations, to work on developing therapies for infectious disease, cancer treatment, and immunotherapies.

“This award is a recognition of the work done by our group over the years and I thank them for their contribution. I sincerely believe that better health comes from better science.”, said by Dr. Pi-Hui Liang.

ImmunAdd, Inc. is a privately held biopharmaceutical company which was founded in 2022 on a mission to improve health through advances in vaccine adjuvants, new formulation, and new drug design. The company is developing next generation saponin adjuvants, new combination of adjuvants and adjuvanted vaccines.

“Innovation for Better Health”

We are ImmunAdd.